Bienvenu Loembé

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors

Marlies H.G. Langenberg, Petronella O. Witteveen, Jeanine M.L. Roodhart et al. · Annals of Oncology · 2011 · 22 citations · Full text

Medicine, Pathology, Advanced Solid Tumors +5

Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial

Ahmad Awada, Thierry Gil, Nicolas Whenham et al. · The Journal of Clinical Pharmacology · 2011 · 20 citations

Oncology, Sorafenib Combined, Mg Bid Sorafenib +10

Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199).

Jeeyun Lee, Seung Tae Kim, Simon A. Smith et al. · Journal of Clinical Oncology · 2020 · 15 citations

Pathology, Weekly Paclitaxel, Normal Dna Replication +18

DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment

Michelle McMullen, Katherine Karakasis, Bienvenu Loembé et al. · International Journal of Gynecological Cancer · 2020 · 14 citations · Full text